Svb Leerink Reaffirms Market Perform Rating for Henry Schein (HSIC)
Svb Leerink reiterated their market perform rating on shares of Henry Schein (NASDAQ:HSIC) in a research note published on Wednesday, BenzingaRatingsTable reports. They currently have a $70.00 price objective on the stock, down from their prior price objective of $75.00.
A number of other research firms have also recently issued reports on HSIC. Barclays lowered their price objective on Henry Schein from $73.00 to $63.00 and set an equal weight rating on the stock in a research report on Thursday, February 21st. Zacks Investment Research cut Henry Schein from a hold rating to a sell rating in a research report on Tuesday, February 26th. UBS Group assumed coverage on Henry Schein in a research report on Thursday, January 17th. They issued a sell rating and a $73.00 price target on the stock. Guggenheim assumed coverage on Henry Schein in a research report on Wednesday, April 17th. They issued a buy rating and a $72.00 price target on the stock. Finally, BidaskClub cut Henry Schein from a hold rating to a sell rating in a research report on Tuesday, January 29th. Six analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $74.27.
Shares of HSIC traded up $0.63 on Wednesday, reaching $67.21. 35,108 shares of the stock traded hands, compared to its average volume of 1,846,621. The stock has a market cap of $9.98 billion, a PE ratio of 16.26, a P/E/G ratio of 2.40 and a beta of 0.89. The company has a current ratio of 1.65, a quick ratio of 0.93 and a debt-to-equity ratio of 0.34. Henry Schein has a 12 month low of $56.58 and a 12 month high of $91.35.
In other Henry Schein news, Director Philip A. Laskawy sold 1,084 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $59.86, for a total value of $64,888.24. Following the transaction, the director now owns 32,899 shares of the company’s stock, valued at $1,969,334.14. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 1.06% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Stephens Investment Management Group LLC boosted its stake in Henry Schein by 3.8% in the first quarter. Stephens Investment Management Group LLC now owns 59,900 shares of the company’s stock worth $3,601,000 after purchasing an additional 2,175 shares in the last quarter. Headinvest LLC boosted its stake in Henry Schein by 100.0% in the fourth quarter. Headinvest LLC now owns 13,160 shares of the company’s stock worth $1,033,000 after purchasing an additional 6,580 shares in the last quarter. Royal London Asset Management Ltd. boosted its stake in Henry Schein by 81.5% in the fourth quarter. Royal London Asset Management Ltd. now owns 154,591 shares of the company’s stock worth $12,046,000 after purchasing an additional 69,421 shares in the last quarter. Steinberg Global Asset Management boosted its stake in Henry Schein by 43.4% in the fourth quarter. Steinberg Global Asset Management now owns 32,661 shares of the company’s stock worth $2,565,000 after purchasing an additional 9,879 shares in the last quarter. Finally, Bell Rock Capital LLC acquired a new position in Henry Schein in the first quarter worth $581,000.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.